Jasub Property Holdings LLP has disclosed the acquisition of 51,00,000 equity shares in Cohance Lifesciences Limited, representing 1.26% of the total voting capital. This transaction, occurring between November 9 and November 11, 2026, was executed via inter-se transfer through block deals. Following the acquisition, Jasub Property Holdings LLP’s total holding in Cohance Lifesciences stands at 5.18%, with the overall voting capital held by the acquirer group at 6.36%.
Share Acquisition in Cohance Lifesciences
Jasub Property Holdings LLP has formally announced a significant acquisition of shares in Cohance Lifesciences Limited (formerly Suven Pharmaceuticals Limited). The disclosure, made pursuant to Regulation 29(2) of SEBI’s Substantial Acquisition of Shares and Takeovers Regulations, 2011, details the acquisition of 51,00,000 equity shares. This transaction increases Jasub Property Holdings LLP’s direct stake to 1.98 crore shares.
Transaction Details and Impact
The acquisition, which involved an inter-se transfer through block deals, took place between November 9, 2026, and November 11, 2026. Prior to this acquisition, the acquirer group, including entities such as Jasti Property and Equity Holdings Private Limited and various individuals associated with the Jasti Family Trust, held approximately 6.36% of the total voting capital. Post-acquisition, the total holding by the acquirer group remains at 6.36%, with Jasub Property Holdings LLP’s share now accounting for 5.18%.
Shareholding Before and After
Before the recent transaction, the acquirer group’s total holding was 2,43,26,009 shares, representing 6.36% of the total voting capital. Specifically, Jasti Property and Equity Holdings Private Limited held 96,16,009 shares (2.51%), and Jasub Property Holdings LLP held 1,47,00,000 shares (3.84%). Following the acquisition of 51,00,000 shares by Jasub Property Holdings LLP, its holding increased to 1,98,00,000 shares (5.18%). The total holding of the acquirer group after this transaction is 2,43,26,009 shares, representing 6.36% of the total voting capital.
The total equity share capital of Cohance Lifesciences Limited before and after the acquisition remains 38,25,97,330 equity shares. The total diluted share capital post-acquisition is 40,59,80,385 shares.
Source: BSE
